港股公告掘金 |海丰国际年度股东应占溢利10.28亿美元，同比增长93.51%

智通财经03-10

【重大事项】国华(00370)附属AI集团拟与中科编易以重组方式建立一间合资公司中国生物制药(01177)：全球首创JAK/ROCK抑制剂“罗伐昔替尼(ROVADICITINIB)”IB/IIA期临床研究结果发表于《血液》翰森制药(03692)：阿美乐® (甲磺酸阿美替尼片)第三项适应症获国家药监局签发药品注册证书高视医疗(02407)全资附属公司达成MDR重要里程碑;及自研亲水性丙烯酸人工晶状体...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2518279342?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-10 23:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518279342","market":"us","top_or_hot":-1,"title":"港股公告掘金 |海丰国际年度股东应占溢利10.28亿美元，同比增长93.51%","media":"智通财经","content":"<div>\n<p>【重大事项】国华(00370)附属AI集团拟与中科编易以重组方式建立一间合资公司中国生物制药(01177)：全球首创JAK/ROCK抑制剂“罗伐昔替尼(ROVADICITINIB)”IB/IIA期临床研究结果发表于《血液》翰森制药(03692)：阿美乐® (甲磺酸阿美替尼片)第三项适应症获国家药监局签发药品注册证书高视医疗(02407)全资附属公司达成MDR重要里程碑;及自研亲水性丙烯酸人工晶状体...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1260086.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股公告掘金 |海丰国际年度股东应占溢利10.28亿美元，同比增长93.51%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股公告掘金 |海丰国际年度股东应占溢利10.28亿美元，同比增长93.51%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-10 23:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1260086.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【重大事项】国华(00370)附属AI集团拟与中科编易以重组方式建立一间合资公司中国生物制药(01177)：全球首创JAK/ROCK抑制剂“罗伐昔替尼(ROVADICITINIB)”IB/IIA期临床研究结果发表于《血液》翰森制药(03692)：阿美乐® (甲磺酸阿美替尼片)第三项适应症获国家药监局签发药品注册证书高视医疗(02407)全资附属公司达成MDR重要里程碑;及自研亲水性丙烯酸人工晶状体...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1260086.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00370","symbol_name":"国华","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1260086.html","article_id":"2518279342","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518279342","pubTimestamp":1741619127,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【重大事项】国华(00370)附属AI集团拟与中科编易以重组方式建立一间合资公司中国生物制药(01177)：全球首创JAK/ROCK抑制剂“罗伐昔替尼(ROVADICITINIB)”IB/IIA期临床研究结果发表于《血液》翰森制药(03692)：阿美乐 (甲磺酸阿美替尼片)第三项适应症获国家药监局签发药品注册证书高视医疗(02407)全资附属公司达成MDR重要里程碑;及自研亲水性丙烯酸人工晶状体(","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"00370":"国华","BK1119":"汽车制造商","IE00BYTNYN87.SGD":"PINEBRIDGE ASIA EX JAPAN SMALL CAP EQUITY \"A5\" (SGD) ACC","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","BK1103":"海运","IE00B12V2V27.USD":"柏瑞亚洲小盘股A(除日本)","YANG":"三倍做空富时中国ETF-Direxion","BK1229":"房地产经营公司","09863":"零跑汽车","BK1191":"制药","IE00BHRH8C09.USD":"LM MARTIN CURRIE ASIA PACIFIC EX JAPAN REAL INC \"A\" (USD) INC","BK1521":"挪威政府全球养老基金持仓","IE00BHRH8D16.HKD":"FTGF MARTIN CURRIE ASIA PACIFIC URBAN TRENDS INCOME \"A\" (HKD) INC","LU1316543674.SGD":"Janus Henderson Horizon Asia-Pacific Property Income A3 SGD","BK1601":"香港本地股","BK1541":"物流","01308":"海丰国际","BK1534":"收租股","BK1181":"经销商","01997":"九龙仓置业","LU2226123227.USD":"Janus Henderson Horizon Asia-Pacific Property Income A5m USD","LU2226123490.SGD":"Janus Henderson Horizon Asia-Pacific Property Income A5m SGD","LU0229494975.USD":"骏利亨德森亚太地产股票基金","BK1258":"房地产运营公司","IE00BG0RBZ43.SGD":"Legg Mason Martin Currie - Asia Pacific Ex Japan Real Income A Mdis SGD Plus","01177":"中国生物制药","BK4614":"Manus概念股","BK1589":"北水核心资产","BK1515":"抗疫概念","HSCEI":"国企指数","IE00BYQNZ168.SGD":"PINEBRIDGE ASIA EX JAPAN SMALL CAP EQUITY \"A5CP\" (SGD) ACC","HSTECH":"恒生科技指数","SG9999011746.SGD":"PINEBRIDGE INTERNATIONAL FUNDS - ACORNS OF ASIA BA (SGD) ACC"},"translate_title":"Hong Kong stock announcement Nuggets SITC International's annual profit attributable to shareholders was US $1.028 billion, a year-on-year increase of 93.51%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00370":0.9,"01177":0.9,"01308":1,"01997":0.9,"09863":0.9,"HSCEI":1,"HSTECH":1,"YANG":1},"content_text":"【重大事项】国华(00370)附属AI集团拟与中科编易以重组方式建立一间合资公司中国生物制药(01177)：全球首创JAK/ROCK抑制剂“罗伐昔替尼(ROVADICITINIB)”IB/IIA期临床研究结果发表于《血液》翰森制药(03692)：阿美乐® (甲磺酸阿美替尼片)第三项适应症获国家药监局签发药品注册证书高视医疗(02407)全资附属公司达成MDR重要里程碑;及自研亲水性丙烯酸人工晶状体(IOL)产品组合获得MDR CE认证滨海投资(02886)与沂水同舟签署合作意向书 拟整合山东沂水县液化气市场千循科技(01640)推出行业首款二手3C交易AI工具贝壳-W(02423)A类普通股获纳入沪港通及深港通越疆(02432)纳入沪港通及深港通下港股通标的证券名单【经营业绩】九龙仓置业(01997)发布年度业绩，基础净盈利同比增加2%至61.39亿港元，拟派第二次中期股息每股0.6港元海丰国际(01308)发布年度业绩，股东应占溢利10.28亿美元，同比增长93.51%零跑汽车(09863)发布年度业绩，收益321.64亿元 同比增长92.06%趣致集团(00917)发布年度业绩，经调整利润2.51亿元 同比增加25.1%中广核新能源(01811)2月完成发电量1478.3吉瓦时，同比增加1.8%华大酒店(00201)、顺豪物业(00219)及顺豪控股(00253)预计年度股东应占除税后而未计及重估及折旧的净溢利同比增加舜宇光学科技(02382)2月手机镜头出货量为约9716.8万件 环比减少8.2% 同比减少6.9%香港中旅(00308)发盈警 预期2024年股东应占利润同比下降不低于40%九毛九(09922)发盈警 预计2024年度股东应占溢利下跌至不少于5000万元如需了解更多详情，请参阅智通财经网(www.zhitongcaijing.com)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.4","shortVersion":"4.33.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518279342"}